These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 28249009)

  • 1. Current use of statins reduces risk of HIV rebound on suppressive HAART.
    Drechsler H; Ayers C; Cutrell J; Maalouf N; Tebas P; Bedimo R
    PLoS One; 2017; 12(3):e0172175. PubMed ID: 28249009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors associated with 10 years of continuous viral load suppression on HAART.
    Bello KJ; Mesner O; O'Bryan TA; Won SH; Lalani T; Ganesan A; Agan BK; Okulicz JF
    BMC Infect Dis; 2016 Jul; 16():351. PubMed ID: 27449671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of first-line antiretroviral therapy failure in HIV-infected Thai children and adolescents.
    Bunupuradah T; Sricharoenchai S; Hansudewechakul R; Klinbuayaem V; Teeraananchai S; Wittawatmongkol O; Akarathum N; Prasithsirikul W; Ananworanich J;
    Pediatr Infect Dis J; 2015 Mar; 34(3):e58-62. PubMed ID: 25478649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of virological failure in HIV-1-infected patients experiencing low-level viraemia under active antiretroviral therapy (ANRS C03 cohort study).
    Vandenhende MA; Perrier A; Bonnet F; Lazaro E; Cazanave C; Reigadas S; Chêne G; Morlat P;
    Antivir Ther; 2015; 20(6):655-60. PubMed ID: 25735799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors associated with mortality among persistently viraemic triple-antiretroviral-class-experienced patients receiving antiretroviral therapy in the HIV Outpatient Study (HOPS).
    Palella FJ; Armon C; Buchacz K; Chmiel JS; Novak RM; D'Aquila RT; Brooks JT;
    J Antimicrob Chemother; 2014 Oct; 69(10):2826-34. PubMed ID: 24942257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterizing the Association Between Alcohol and HIV Virologic Failure in a Military Cohort on Antiretroviral Therapy.
    Deiss RG; Mesner O; Agan BK; Ganesan A; Okulicz JF; Bavaro M; Lalani T; O'Bryan TA; Bebu I; Macalino GE
    Alcohol Clin Exp Res; 2016 Mar; 40(3):529-35. PubMed ID: 26916712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy.
    Geretti AM; Smith C; Haberl A; Garcia-Diaz A; Nebbia G; Johnson M; Phillips A; Staszewski S
    Antivir Ther; 2008; 13(7):927-36. PubMed ID: 19043927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between use of HMG CoA reductase inhibitors and mortality in HIV-infected patients.
    Moore RD; Bartlett JG; Gallant JE
    PLoS One; 2011; 6(7):e21843. PubMed ID: 21765919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trends in Prevalence of HIV-1 Drug Resistance in a Public Clinic in Maputo, Mozambique.
    Bila DC; Boullosa LT; Vubil AS; Mabunda NJ; Abreu CM; Ismael N; Jani IV; Tanuri A
    PLoS One; 2015; 10(7):e0130580. PubMed ID: 26151752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Any impact of blips and low-level viraemia episodes among HIV-infected patients with sustained virological suppression on ART?
    Pernas B; Grandal M; Pertega S; Cañizares A; Castro-Iglesias Á; Mena Á; Rodriguez-Osorio I; Tabernilla A; Pedreira JD; Poveda E
    J Antimicrob Chemother; 2016 Apr; 71(4):1051-5. PubMed ID: 26702924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: data from the ICONA cohort.
    Saracino A; Lorenzini P; Lo Caputo S; Girardi E; Castelli F; Bonfanti P; Rusconi S; Caramello P; Abrescia N; Mussini C; Monno L; d'Arminio Monforte A;
    Clin Microbiol Infect; 2016 Mar; 22(3):288.e1-8. PubMed ID: 26551839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL.
    Madeddu G; Rusconi S; Cozzi-Lepri A; Di Giambenedetto S; Bonora S; Carbone A; De Luca A; Gianotti N; Di Biagio A; Antinori A;
    Infection; 2017 Aug; 45(4):521-528. PubMed ID: 28477212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is Impact of Statin Therapy on All-Cause Mortality Different in HIV-Infected Individuals Compared to General Population? Results from the FHDH-ANRS CO4 Cohort.
    Lang S; Lacombe JM; Mary-Krause M; Partisani M; Bidegain F; Cotte L; Aslangul E; Chéret A; Boccara F; Meynard JL; Pradier C; Roger PM; Tattevin P; Costagliola D; Molina JM;
    PLoS One; 2015; 10(7):e0133358. PubMed ID: 26200661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lopinavir/ritonavir-based antiretroviral therapy in human immunodeficiency virus type 1-infected naive children: rare protease inhibitor resistance mutations but high lamivudine/emtricitabine resistance at the time of virologic failure.
    Frange P; Briand N; Avettand-fenoel V; Veber F; Moshous D; Mahlaoui N; Rouzioux C; Blanche S; Chaix ML
    Pediatr Infect Dis J; 2011 Aug; 30(8):684-8. PubMed ID: 21427626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Level of viral load and antiretroviral resistance after 6 months of non-nucleoside reverse transcriptase inhibitor first-line treatment in HIV-1-infected children in Mali.
    Germanaud D; Derache A; Traore M; Madec Y; Toure S; Dicko F; Coulibaly H; Traore M; Sylla M; Calvez V; Marcelin AG
    J Antimicrob Chemother; 2010 Jan; 65(1):118-24. PubMed ID: 19933171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence of Postsuppression Virologic Rebound in Perinatally HIV-Infected Asian Adolescents on Stable Combination Antiretroviral Therapy.
    Sudjaritruk T; Aurpibul L; Ly PS; Le TPK; Bunupuradah T; Hansudewechakul R; Lumbiganon P; Chokephaibulkit K; Nik Yusoff NK; Nguyen LV; Mohd Razali KA; Fong MS; Nallusamy RA; Kurniati N; Do VC; Boettiger DC; Sohn AH; Kariminia A
    J Adolesc Health; 2017 Jul; 61(1):91-98. PubMed ID: 28343759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Time to viral load suppression in antiretroviral-naive and -experienced HIV-infected pregnant women on highly active antiretroviral therapy: implications for pregnant women presenting late in gestation.
    Aziz N; Sokoloff A; Kornak J; Leva NV; Mendiola ML; Levison J; Feakins C; Shannon M; Cohan D
    BJOG; 2013 Nov; 120(12):1534-47. PubMed ID: 23924192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sustained HIV viral suppression following treatment interruption: an observational study.
    Bedimo R; Chen RY; Westfall AO; Raper JL; Allison JJ; Saag MS
    AIDS Res Hum Retroviruses; 2006 Jan; 22(1):40-4. PubMed ID: 16438644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prolonged statin administration does not act on the cell-mediated immunity of HIV-infected dyslipidemic patients treated with a steady and effective highly active antiretroviral therapy. A two-year prospective study of statin versus fibrate administration.
    Manfredi R; Calza L; Chiodo F
    J Biol Regul Homeost Agents; 2006; 20(1-2):1-9. PubMed ID: 18088548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.